Cyclin D3 has been shown to play a major role in the regulation of cell cycle progression in lymphocytes. It is therefore important to understand the mechanisms involved in the regulation of this protein. We have previously shown that both basal and cAMP-induced degradation of cyclin D3 in Reh cells is dependent on Thr-283 phosphorylation by glycogen synthase kinase-3b (GSK-3b). We now provide evidence of an alternative mechanism being involved in the regulation of cyclin D3 degradation. Treatment of lymphoid cells with okadaic acid (OA), an inhibitor of protein phosphatases 1 and 2A (PP1 and PP2A), induces rapid phosphorylation and proteasomal degradation of cyclin D3. This degradation is not inhibited by the GSK-3b inhibitors lithium or Kenpaullone, or by substitution of Thr-283 with Ala on cyclin D3, indicating that cyclin D3 can be degraded independently of Thr-283 phosphorylation and GSK-3b activity. Interestingly, in vitro experiments revealed that PP1, but not PP2A, was able to dephosphorylate cyclin D3 efficiently, and PP1 was found to associate with His-tagged cyclin D3. These results support the hypothesis that PP1 constitutively keeps cyclin D3 in a stable, dephosphorylated state, and that treatment of cells with OA leads to phosphorylation and degradation of cyclin D3 through inhibition of PP1.
Introduction D-type cyclins are the first group of cyclins to be expressed when mammalian cells are released from quiescence as a response to growth factor stimulation (reviewed in Sherr, 1993) . They assemble with either cdk4 or cdk6 to promote G1 progression by phosphorylating the retinoblastoma protein family members pRB, p107 and p130, thereby inactivating their growth suppressive properties (reviewed in Weinberg, 1995) . Cyclin D-cdk complexes have also been reported to have a noncatalytic role in G1 progression by titrating the cdk inhibitors p21
Cip1 and p27 Kip1 preventing them from inactivating the cyclin E-cdk2 complexes (reviewed in Sherr and Roberts, 1999) . Cyclin D expression is induced by mitogen stimulation, and growth factor withdrawal results in G1 arrest associated with rapid disappearance of cyclin D (Matsushime et al., 1992; Sherr, 1994) . Hence, D-type cyclins act as growth sensors and provide a link between mitogenic stimuli and the cell cycle machinery.
D-type cyclins have been shown to be both necessary and rate limiting for G1 progression (Ando et al., 1993; Baldin et al., 1993; Quelle et al., 1993; Bartkova et al., 1998) , and they are found to be overexpressed in several human cancers (Hall and Peters, 1996; Filipits et al., 2002; Bergsagel et al., 2005) . Furthermore, cyclin D3 has been shown to play a major role in regulating the cell cycle in lymphocytes (Miyatake et al., 1995; Boonen et al., 1999) . It is therefore important to elucidate the mechanisms involved in the regulation of cyclin D3 expression.
The synthesis of D-type cyclins has been shown to be regulated both at the level of transcription (Aktas et al., 1997; Shtutman et al., 1999; Bakiri et al., 2000) and translation (Muise-Helmericks et al., 1998; Takuwa et al., 1999; Naderi et al., 2000; Gutzkow et al., 2003) . In addition, the expression of D-type cyclins is also subjected to post-translational regulation. Several cyclins have been shown to be targeted for proteasomal degradation by phosphorylation, including cyclin E, cyclin D1 and cyclin D3 (Won and Reed, 1996; Diehl et al., 1997; Naderi et al., 2004) . We recently demonstrated that proteasomal degradation of cyclin D3 in Reh cells is dependent on its phosphorylation at Thr-283 by glycogen synthase kinase-3b (GSK-3b) (Naderi et al., 2004) . Generally, the phosphorylation state of a protein depends not only on the activity of protein kinases but also on the activity and accessibility of protein phosphatases. Earlier studies have focused on the role of protein kinases in the regulation of cyclin D degradation, but little is known about the involvement of protein phosphatases in this process. Phosphatases of the phospho-protein phosphatase (PPP) family, which are all Ser/Thr-specific protein phosphatases, have been shown to be essential in cell cycle regulation. For instance, microinjection of PP1-neutralizing antibodies into rat fibroblasts has been reported to induce mitotic arrest (Fernandez et al., 1992) . Furthermore, both PP1 and PP2A have been shown to play a role in the G1/S transition in mammalian cells through regulating the level of pRB phosphorylation (Yan and Mumby, 1999) .
The PPP family is divided into the subfamilies PP1, PP2A (including PP4 and PP6), PP2B and PP5 (reviewed in Bollen and Beullens, 2002) , but PP1 and PP2A are thought to be the dominant protein Ser/Thr phosphatases in vivo (Cohen et al., 1990; Oliver and Shenolikar, 1998) . Okadaic acid (OA), which is a selective inhibitor of PP1 and PP2A (Bialojan and Takai, 1988) , has been extensively used over the past several years to elucidate the role played by PP1 and PP2A in the regulation of several cellular processes.
In the present study, we provide evidence for a novel pathway involved in regulating the stability of cyclin D3, in which PP1 constitutively dephosphorylates cyclin D3, keeping it in a stable, dephosphorylated state.
Results

OA increases the degradation of cyclin D3
We have previously shown that cAMP induces degradation of cyclin D3 in the B-precursor cell line Reh (Naderi et al., 2004) . The mechanism was shown to involve phosphorylation of cyclin D3 by the Ser/Thr kinase GSK-3b, which marks the protein for proteasomal degradation. Since proteins are regulated not only by phosphorylation by kinases but also by dephosphorylation by phosphatases, we wished to investigate the involvement of phosphatases in the degradation of cyclin D3 in Reh cells. To do so, cells were treated with or without the phosphatase inhibitor OA (750 nM) for 2 h before the level of cyclin D3 was examined by immunoblotting. As shown in Figure 1a , OA markedly reduced the level of cyclin D3. Treatment of cells with different concentrations of OA revealed that cyclin D3 degradation was insensitive to low concentrations of OA (50-100 nM), whereas higher concentrations of OA (250-750 nM) reduced the expression of cyclin D3 in a dose-dependent manner (Figure 1b) . To examine whether this reduction was at the level of degradation, Reh cells were preincubated with cycloheximide, which inhibits protein synthesis, before treatment with or without OA. The expression of cyclin D3 was then examined by Western blot analysis. We observed that the level of cyclin D3 was reduced in cells treated with OA in the presence of cycloheximide compared to cycloheximide treatment alone (Figure 1c and d) , and the effect was noted already after 20 min. Furthermore, OA did not have any effect on the steady state of cyclin D3 mRNA (data not shown). These results indicate that OA increases the degradation of cyclin D3.
OA-induced degradation of cyclin D3 involves the proteasomal pathway The ubiquitin/proteasome system is the major pathway for selective protein degradation in eucaryotic cells (reviewed in Kornitzer and Ciechanover, 2000) . As previously reported in Reh cells, both basal and cAMPinduced degradation of cyclin D3 involves this pathway (Naderi et al., 2004) . It was therefore of interest to investigate whether proteasomes also played a role in OA-induced degradation of cyclin D3. Reh cells were treated with or without OA for 2 h in the presence or absence of the proteasome inhibitors MG-132 (Figure 2a) or LLnL (Figure 2b ). Western blot analysis revealed that both inhibitors abolished the OA-induced downregulation of cyclin D3, demonstrating that proteasomes are involved in OA-induced degradation of cyclin D3. Of note is that OA treatment resulted in a cyclin D3 form with slower mobility (discussed below). We have earlier found that both basal and cAMP-induced degradation of cyclin D3 occur in the nucleus, and is not preceded by cytosolic translocation of cyclin D3 (Naderi et al., 2004) . Similarly, immunofluorescent staining for cyclin D3 revealed that OA had no effect on the cellular localization of cyclin D3 (Figure 3) . Cotreatment of cells with OA and MG-132 resulted in accumulation of cyclin D3 only within the nucleus.
OA leads to phosphorylation of cyclin D3 Several cyclins have been shown to be targeted for proteolysis by phosphorylation, including cyclin D3, cyclin D1 and cyclin E (Won and Reed, 1996; Diehl et al., 1997; Naderi et al., 2004) . To examine whether the observed shift in the mobility of cyclin D3 induced by OA was due to phosphorylation, we performed phosphatase assay on total Reh cell lysate. As shown in the immunoblot in Figure 4 , treatment of the lysates with calf intestinal alkaline phosphatase (CIAP) reversed the mobility of cyclin D3 similar to the band seen in untreated cells. This shift in cyclin D3 mobility was not an artefact resulting from proteolysis of cyclin D3, since treatment with a mixture of protein phosphatase inhibitors abolished the effect of CIAP. Taken together, these results indicate that the retarded cyclin D3 band seen in cells treated with OA is due to phosphorylation.
GSK-3b is not involved in OA-induced degradation of cyclin D3 Since both basal and cAMP-induced degradation of cyclin D3 is shown to be dependent on phosphorylation by the Ser/Thr kinase GSK-3b (Naderi et al., 2004) , we next wanted to examine whether this kinase is also important for the OA-induced degradation of cyclin D3. In this context, Reh cells were treated with the GSK-3b inhibitors Kenpaullone or LiCl in the presence or absence of OA. Interestingly, inhibition of GSK-3b did not affect the degradation of cyclin D3 by OA (Figure 5a and b), in contrast to the basal and forskolininduced degradation, which were both abolished in the presence of GSK-3b inhibitors (Naderi et al., 2004) . Furthermore, Kenpaullone did not eliminate the observed shift in cyclin D3 mobility after cotreatment of cells with OA and MG-132 ( Figure 5c ). Taken together, these results indicate that GSK-3b is not involved in OA-induced phosphorylation and degradation of cyclin D3, implying that cyclin D3 is degraded by both GSK-3b-dependent (Naderi et al., 2004) and GSK-3b-independent pathways.
Mutation of Thr-283 does not prevent OA-mediated degradation of cyclin D3 Inhibition of GSK-3b using LiCl or Kenpaullone did not affect the degradation of cyclin D3 by OA (see Figure 5 ), indicating that this kinase is not involved in OA-induced degradation of cyclin D3. To further strengthen this suggestion, we investigated the stability of cyclin D3 mutated at Thr-283, since phosphorylation at this site has shown to be required for the GSK-3b-mediated degradation of cyclin D3 (Naderi et al., 2004) . Thus, Reh cells transfected with His-cyclin D3 (wt) or His-cyclin D3 (T283A) vectors were treated with or without OA. Western blot analyses revealed that substitution of Thr-283 with Ala did not affect the OA-induced downregulation of cyclin D3, whereas forskolin-induced downregulation of cyclin D3 was abolished (Figure 6a) . To obtain more direct evidence that the OA-induced downregulation of exogenous cyclin D3 was at the level of degradation, transfected Reh cells were treated with or without OA after preincubation with the protein synthesis inhibitor cycloheximide. The level of cyclin D3 was analysed by immunoblotting with anti-cyclin D3 antibodies. As shown in Figure 6b , treatment of OA increased the degradation of both exogenous and endogenous cyclin D3. As expected, mutation of the GSK-3b phosphorylation site Thr-283 on cyclin D3 stabilized the basal level of cyclin D3, but it did not affect the stability of cyclin D3 in the presence of OA. Thus, GSK-3b does not appear to be required for OA-induced degradation of cyclin D3. To further demonstrate that OA leads to phosphorylation of cyclin D3 at a site other than Thr-283, we performed phosphatase assay on lysates from Reh cells nucleofected with His-cyclin D3 (wt) or His-cyclin D3 (T283A) vectors that were cotreated with OA and MG-132. As shown in Figure 6c , treatment with OA and MG-132 resulted in a shift in mobility of both His-cyclin D3 (wt) and His-cyclin D3 (T283A). This shift was due to phosphorylation, since treatment of lysates with CIAP reversed the mobility of exogenous cyclin D3 similar to the band seen in untreated cells. Taken together, these results support a notion that several different phosphorylation sites are important for degradation of cyclin D3. The OA-mediated degradation of cyclin D3 is not limited to Reh cells, since the same effect was noted in both Jurkat T cells and 293 human embryonic kidney cells (Figure 7 ).
PEST sequences are not involved in OA-mediated degradation of cyclin D3 PEST sequences, sequences enriched in proline (P), glutamate (E), serine (S) and threonine (T), are present in a variety of rapidly degraded proteins and have been proposed to target these proteins for degradation (reviewed in Rechsteiner and Rogers, 1996) . Using the program PESTfind, we identified two putative PEST elements at the C-terminal of cyclin D3 (Figure 8 ). Therefore, we wished to examine whether one or several of the Ser and/or Thr within the PEST sequences of cyclin D3 were required for the OA-induced degradation of cyclin D3. To address this possibility, Reh cells were nucleofected with His-tagged cyclin D3 mutated at the different Ser and Thr within the PEST sequences, followed by treatment with or without OA for 2 h in the presence or absence of the proteasome inhibitor MG-132. Expression of exogenous cyclin D3 was then analysed by Western blot analysis using antibodies against cyclin D3. As shown in Figure 9 , neither of the mutant cyclin D3 constructs abolished the effect of OA on the stability of cyclin D3. Furthermore, treatment with MG-132 revealed that all the His-cyclin D3 mutants exhibited a slower mobility when treated with OA, suggesting that OA-induced degradation of cyclin D3 requires phosphorylation of cyclin D3 at a site outside the two PEST regions.
PP1 dephosphorylates cyclin D3 in vitro
Our data show that cyclin D3 accumulates in a phosphorylated form in Reh cells treated with a combination of OA and proteasome inhibitors. This could either be due to activation of a cyclin D3-specific kinase other than GSK-3b or inhibition of a cyclin D3-specific phosphatase. Possible candidates for such phosphatases would be PP1 or PP2A, since OA is known to inhibit these two phosphatases (Bialojan and Takai, 1988) . To test this possibility, we immunoprecipitated cyclin D3 from cells treated with OA and MG-132, and used it as substrate in PP1 and PP2A enzyme assays. Western blot analysis revealed that PP1 was able to efficiently dephosphorylate cyclin D3, whereas only marginal effect was observed with PP2A ( Figure 10 ). The dephosphorylation of cyclin D3 by PP1 was blocked by OA, demonstrating that the shift in mobility of cyclin D3 was due to dephosphorylation, and not an artefact resulting from proteolysis of cyclin D3. These results support the hypothesis that PP1 constitutively dephosphorylates cyclin D3 in Reh cells, and that OA treatment leads to phosphorylation of cyclin D3 by inhibiting PP1.
Association between cyclin D3 and PP1 in vitro To provide further evidence for the role of PP1 in dephosphorylation of cyclin D3 in Reh cells, an in vitro pulldown assay with bacterially expressed His-tagged cyclin D3 (wt) as bait was performed. Cyclin D3 (wt) immobilized to Ni-NTA agarose beads was incubated with total cell lysates from Reh cells treated with or without MG-132 and OA. The adsorbed material was then analysed by immunoblotting with anti-PP1 antibodies. As shown in Figure 11 , cyclin D3 associated with PP1 present in the lysates. This binding was specific as Ni-NTA agarose beads alone did not bind to PP1. Taken together, these results support a role for PP1 as the phosphatase responsible for dephosphorylating cyclin D3 in Reh cells.
Discussion
D-type cyclins play a critical role in promoting G1
progression, and it is therefore important to understand the mechanisms involved in the regulation of their expression. Over the past several years, regulated protein degradation has been shown to be a key mechanism in cell cycle regulation. Several cyclins have been reported to be targeted for the ubiquitin/proteasome pathway through site-specific phosphorylation, including cyclin D3, cyclin D1 and cyclin E (Won and Reed, 1996; Diehl et al., 1997; Naderi et al., 2004) . Whereas the role of protein kinases in the regulation of cyclin D degradation is well studied, little is known about the involvement of phosphatases in this process. In the present study, we used OA to elucidate the role of PP1 and PP2A in the degradation of cyclin D3 in the Bprecursor cell line Reh. We demonstrate that treatment with OA promotes rapid phosphorylation and proteasomal degradation of cyclin D3. This degradation was found to be independent of Thr-283 phosphorylation and GSK-3b activity. Furthermore, in vitro experiments support the hypothesis that OA induces degradation of cyclin D3 by inhibiting PP1 from constitutively dephosphorylating cyclin D3, keeping it in a stable, dephosphorylated state. Taken together, our results suggest the involvement of an additional pathway in the degradation of cyclin D3. Interestingly, OA also induced phosphorylation and proteasomal degradation of cyclin D3 in Jurkat T cells and 293 human embryonic kidney cells, indicating that this pathway might be a general mechanism for cyclin D3 degradation.
Previous studies in our lab have shown that both basal and cAMP-induced degradation of cyclin D3 is dependent on phosphorylation at Thr-283 by the Ser/ Thr-kinase GSK-3b (Naderi et al., 2004) . It was therefore of interest to investigate whether the OAinduced degradation of cyclin D3 involved the same mechanism. However, treatment with the GSK-3b inhibitors Kenpaullone or LiCl did not abolish the effect of OA on cyclin D3 degradation. Furthermore, mutation of the GSK-3b phosphorylation site Thr-283 on cyclin D3 did not stabilize the protein in the presence of OA. We therefore propose that cyclin D3 is degraded by at least two distinct mechanisms, only one of which is dependent on GSK-3b activity. Our results are consistent with the recent finding that retinoic acid induces proteasomal degradation of cyclin D3 in HBE cells independent of Thr-283 on cyclin D3 and GSK-3b inhibition (Ma et al., 2005) . Also, both cyclin E and cyclin D1 have been shown to be degraded by two different mechanisms. Free cyclin E and cyclin D1 are ubiquitinated and degraded independently of their phosphorylation on Thr-380 by cdk2 and Thr-286 by GSK-3b, respectively, whereas ubiquitination of cdkbound cyclin E and cyclin D1 require phosphorylation of these sites (Won and Reed, 1996; Singer et al., 1999; Germain et al., 2000) .
PEST sequences are present in a variety of rapidly degraded proteins and have been proposed to target these proteins for degradation (reviewed in Rechsteiner and Rogers, 1996) . The PEST sequences are often latent signals that have to be activated to induce degradation, and a common mechanism for activation is phosphorylation of Ser and Thr within the sequence (Rechsteiner and Rogers, 1996) . Using the program PESTfind, we identified two putative PEST elements at the C-terminal of cyclin D3, and we focused on these regions in our attempt to identify the site(s) phosphorylated by OA in vivo. Mutation of the Ser or Thr residues in the PEST sequences did not prevent the effect of OA on the stability of cyclin D3. Thus, OA-induced degradation of cyclin D3 appears to require phosphorylation of cyclin D3 at a site outside the two PEST sequences. Still, we cannot rule out the possibility that the PEST sequences might be important for the degradation of cyclin D3. Brown et al. (1997) have suggested that the high degree of negative charge, and thus likely lack of structure within the PEST sequences, may be important for proper unfolding of the protein after docking with the proteasomes. It should however be noted that PEST sequences are also found in stable proteins, indicating that PEST sequences are not always linked to degradation of proteins (Rogers et al., 1986) .
Recent reports indicate that cyclin D3 degradation is subjected to regulation by several stimuli. For instance, both tumor necrosis factor and hyposmotic stress induce proteasomal degradation of cyclin D3 (Hu et al., 2002; Tao et al., 2002) . Furthermore, Casanovas et al. (2004) has shown that the MAP kinase p38 SAPK2 phosphorylates cyclin D3 at Thr-283, and that this phosphorylation marks the protein for proteasomal degradation. To examine whether p38 SAPK2 is involved in OA-induced degradation of cyclin D3, we treated the cells with the p38 SAPK2 -specific inhibitor SB203580. However, treatment with the p38 SAPK2 inhibitor did not prevent the OAinduced degradation of cyclin D3 in our cell system (data not shown), suggesting that the effect of OA on cyclin D3 stability is independent of p38 SAPK2 activity. This result was expected, since degradation of cyclin D3 was shown to be independent of Thr-283 phosphorylation in our system. Thus, it seems that the degradation of cyclin D3 can proceed through different pathways depending on stimuli and cell type.
Another kinase that has been shown to phosphorylate D-type cyclins is the Arg-directed Ser/Thr kinase Mirk/ dyrk1B. In Mv1Lu lung epithelial cells, Mirk/dyrk1B kinase phosphorylated cyclin D1 at Thr-288 and increased its degradation (Zou et al., 2004) . Since there is a high degree of homology between cyclin D1 and cyclin D3 (Thr-288 on cyclin D1 is equivalent to Thr-285 on cyclin D3), this kinase might also regulate the -3) , or Ni-NTA agarose beads alone (lanes 4-6), were incubated with total cell lysate (750 mg) from untreated Reh cells or Reh cells treated with MG-132 and OA (as described in the legend to Figure 2 ). In lanes 3 and 6, the beads were incubated in lysis buffer as negative controls. After washing four times in lysis buffer, the adsorbed material was resolved on SDS-PAGE followed by immunoblot analysis using antibodies against PP1 (upper panel). Ponceau staining shows the amount of the bait protein (lower panel).
degradation of cyclin D3. To address this possibility, we treated the cells with the MEK1 inhibitors PD98059 or U0126, since blocking the MEK1-Erk pathway has been shown to induce Mirk/dyrk1B transcription (Deng et al., 2003) . However, inhibition of the MEK1-Erk pathway did not abolish the effect of OA on cyclin D3 degradation (data not shown), suggesting that Mirk/ dyrk1B is not involved in this process in Reh cells. This result is in agreement with the observation that OA activates the MEK-Erk pathway in Reh cells (data not shown).
PP1 and PP2A, the dominant protein Ser/Thr phosphatases in vivo (Cohen et al., 1990; Oliver and Shenolikar, 1998) , have been shown to be essential in cell cycle regulation. Fernandez et al. (1992) have reported that microinjection of PP1-neutralizing antibodies into rat fibroblasts induced mitotic arrest. Furthermore, PP1 and PP2A have been shown to play a role in the G1/S transition through regulating the level of pRB phosphorylation (Yan and Mumby, 1999) . Our results indicate that PP1 and/or PP2A also play a role in the regulation of cyclin D3 expression. We entertain two possible mechanisms by which OA may induce phosphorylation and degradation of cyclin D3. OA may induce degradation of cyclin D3 by preventing PP1 or PP2A from directly dephosphorylating cyclin D3 at a site distinct from Thr-283. Alternatively, OA may promote degradation of cyclin D3 by indirectly phosphorylating and activating a hitherto unidentified cyclin D3 kinase. We pursued the first of these alternatives, and found that PP1, but not PP2A, efficiently dephosphorylated cyclin D3 in vitro. Furthermore, an in vitro pulldown assay revealed that PP1 was able to associate with His-tagged cyclin D3. Our results support a model whereby PP1 constitutively dephosphorylates cyclin D3, and that treatment of cells with OA inhibits PP1, resulting in phosphorylation and degradation of cyclin D3. However, further experiments are required to clarify the role of PP1 in the degradation of cyclin D3 in vivo.
Materials and methods
Reagents and antibodies
Okadaic acid, kenpaullone and forskolin were obtained from Calbiochem. Cycloheximide, LiCl, LLnL, MG-132, NaF, Na 3 VO 4 and b-glycerophosphate were from Sigma. Purified PP2A was obtained from Upstate and purified PP1 was a kind gift from Dr Mathieu Bollen (Katholieke University, Leuven, Belgium). CIAP was purchased from Promega. Monoclonal anti-cyclin D3 (DCS-22, for Western blot analysis) was purchased from Medical & Biological Laboratories (MBL), and polyclonal anti-cyclin D3 (AHF-0152, for immunoprecipitation and immunofluorescence staining) was from Biosource. Anti-actin (C-2) was from Santa Cruz Biotechnology. Anti-PP1 (06-221) was obtained from Upstate.
Cells
The B-lymphoid precursor cell line Reh (originally provided by Dr MF Greaves (Imperial Cancer Research Fund Laboratories, London, UK)) and the leukemic T-cell line Jurkat (clone E6.1, ATCC) were cultured at a density between 0.15 Â 10 6 and 1.3 Â 10 6 cells/ml in RPMI 1640 (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (GIBCO), 2 mM glutamine, 125 U/ml penicillin and 125 mg/ml streptomycin in 5% CO 2 at 371C. The Flp-IntT-RExt-293 cell line (Invitrogen), derived from 293 human embryonic kidney cells, were grown in Dulbecco's modified Eagle's medium (Invitrogen) and supplemented as described above.
Construction of expression vectors
The vectors His-cyclin D3 (wt) and His-cyclin D3 (T283A) were generated by cloning the full-length cyclin D3 (wt or T283A) cDNA into the BamH1/EcoR1 sites of the pEF1/HisC vector (Invitrogen) as previously described (Naderi et al., 2004) . The other His-tagged cyclin D3 constructs were generated in the His-cyclin D3 (wt) or His-cyclin D3 (T283A) plasmids, using the QuickChange Site-directed Mutagenesis method of Stratagene. To confirm the mutated sequences, all of the mutant cyclin D3 constructs were sequenced.
Transient transfection
Reh cells were transiently transfected as previously described (Naderi et al., 2004) , or they were nucleofected using the Cell Line Nucleofector Kit R (Amaxa Biosystems), program G-16 and 10 mg of expression vector according to the manufacturer's protocol. After transfection/nucleofection, the cells were incubated in growth medium for 20 h before treatment. Total cell lysates were prepared in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5 mM EDTA, 50 mM NaF, 1 mM Na 3 VO 4 , 10mM b-glycerophosphate, 0.2 mM PMSF, 10 mg/ml leupeptin and 0.5% aprotinin) and then subjected to SDS-PAGE and immunoblot analysis.
Pulldown assay
To generate bait for pulldown experiments, bacterially expressed histidine-tagged cyclin D3 (wt), His-cyclin D3 (wt), was affinity purified under denaturing conditions using the Ni-NTA purification system (Qiagen) as previously described (Naderi et al., 2004) . In total, 10 ml of a 1:1 slurry of His-cyclin D3 (wt)-coated Ni-NTA agarose beads, or Ni-NTA agarose beads alone, were washed three times in lysis buffer (50 mM Tris-HCl, pH 7.5, 130 mM NaCl, 5 mM EDTA, 0.1% NP-40, 10 mM NaF, 1 mM Na 3 VO 4 , 1 mM PMSF, 5 mg/ml aprotinin and 5 mg/ml leupeptin). The beads were subsequently incubated with 750 mg of total Reh cell lysate prepared in the same lysis buffer for 2 h at 41C with rotation. After washing four times in lysis buffer, the adsorbed material was eluted by boiling for 10 min in 1 Â SDS sample buffer, and then separated on 10% SDS-PAGE followed by Western blot analysis.
Immunoprecipitation
For immunoprecipitation of cyclin D3, 500 mg of total Reh cell lysate prepared in RIPA buffer was incubated with polyclonal anti-cyclin D3 antibodies (2 mg) for 2 h at 41C with rotation. Then, 35 ml of a 1:1 slurry of protein A sepharose beads (Amersham Pharmacia Biotech) was added to the lysate and the incubation was continued for another hour at the same conditions. The resulting immunocomplexes were washed twice in RIPA buffer and twice in phosphatase assay buffer.
Phosphatase assay
Immunoprecipitated cyclin D3 was resuspended in 200 ml phosphatase assay buffer, either PP2A buffer (Upstate) or PP1 buffer (25 mM Tris-HCl, pH 7.4, 0.5 mM DTT and 1 mg/ml BSA), before aliquoted in 20 ml aliquotes (the amount used per assay). The aliquotes were stored at À801C. Assays were carried out in a final volume of 40 ml in phosphatase assay buffer supplemented with purified phosphatases (PP2A or PP1). After 30 min of incubation at 371C, the reactions were terminated by adding 3 Â SDS sample buffer (8 ml). The samples were then boiled for 10 min followed by Western blot analysis.
Total Reh cell lysate (50 mg) prepared in RIPA buffer (without protein phosphatase inhibitors) was treated with 200 U/ml CIAP for 30 min at 371C in the presence or absence of protein phosphatase inhibitors (10 mM b-glycerophosphate, 1 mM Na 3 VO 4 and 20 mM NaF). The reactions were terminated by adding 3 Â SDS sample buffer. After boiling for 5 min, the samples were subjected to immunoblot analysis.
Immunoblotting and immunofluorescence staining Reh cells were lysed in RIPA buffer before protein concentration was determined using the Bradford method (BioRad). Equal amounts of protein were separated on a 10% SDS-PAGE and subsequently transferred to a nitrocellulose membrane (Amersham Pharmacia Biotech) using a semidry transfer cell (Bio-Rad). The proteins were detected using the appropriate primary antibodies and the enhanced chemiluminescence detection system (ECL Plus, Amersham Pharmacia Biotech) according to the manufacturer's protocol. Immunofluorescence staining was performed as described previously (Naderi et al., 2004) .
